MEDICALSYSTEM(SZ:300439) Shang Hai Zheng Quan Bao·2025-04-18 22:22Core Viewpoint - The company, Meikang Biomedical, reported a decrease in revenue for the year, primarily due to a decline in agency product and testing service income, while maintaining a stable net profit growth [9]. Company Overview - Meikang Biomedical focuses on the research, production, and sales of in vitro diagnostic products, as well as providing third-party medical diagnostic services. The company aims to enhance its competitiveness by integrating diagnostic instruments, products, and services [4][5]. Business Performance - The company achieved operating revenue of 1,742.42 million yuan, a year-on-year decrease of 7.61%. The decline was attributed to reduced income from agency products and testing services. However, self-produced products maintained revenue of 837.16 million yuan, unchanged from the previous year [9]. - The net profit attributable to shareholders was 257.9972 million yuan, reflecting a year-on-year increase of 0.56%. The net profit after deducting non-recurring gains and losses was 220.4061 million yuan, up 12.67% compared to the previous year [9]. Product and Service Offerings - The company offers a wide range of in vitro diagnostic reagents and instruments, as well as third-party medical diagnostic services. It has established strategic partnerships with international brands like Hitachi, Roche, and Thermo Fisher to meet the needs of various medical institutions [7]. - The company has developed a comprehensive product line covering biochemical, chemiluminescence, mass spectrometry, and molecular diagnostics, among others. It has obtained 459 product registration certificates for in vitro diagnostic reagents and 49 for instruments [7][8]. Strategic Initiatives - The company launched a smart laboratory solution based on the ISO15189 quality management system, which includes a laboratory information management system (LIMS) and a smart management platform [8]. - The company plans to continue investing in research and development, optimize product structure, and enhance product quality and market competitiveness to adapt to the evolving healthcare landscape [9]. Shareholder and Stock Information - The company approved a profit distribution plan, proposing a cash dividend of 1.35 yuan per 10 shares, with no bonus shares issued [3]. - The company also initiated a restricted stock incentive plan, granting 950,000 shares at a price of 6.13 yuan per share to eligible participants [15].